^
    2ms
    Molecular alterations of breast carcinoma: a single-centre experience (ECP 2024)
    Due to the majority of cases in our study being constituted of triple-negative cases, TP53 mutation, which is reported to be more common in these cases in the literature, was observed frequently. Most of the mutations we detected in our study have been reported to be associated with prognostic, predictive, and drug resistance implications, making their identification in breast tumours significant.
    Clinical • BRCA Biomarker
    |
    KRAS (KRAS proto-oncogene GTPase) • ER (Estrogen receptor) • TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • BRCA1 (Breast cancer 1, early onset) • MSI (Microsatellite instability) • PTEN (Phosphatase and tensin homolog) • IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • AKT1 (V-akt murine thymoma viral oncogene homolog 1) • BRCA (Breast cancer early onset) • CDH1 (Cadherin 1)
    |
    TP53 mutation • KRAS mutation • BRCA1 mutation • PIK3CA mutation • PTEN mutation • CDH1 mutation • PIK3CA mutation + PTEN mutation
    |
    BRCA MASTR Plus Dx
    6ms
    Chemotherapy response score (CRS) and efficacy of PARP inhibitor (PARPi) treatment in advanced epithelial ovarian cancer (AEOC) (ESMO-GC 2024)
    22 patients (48%) received PARPi (2 olaparib, 10 niraparib). Due to small sample, we did not find any statistical differences on PFS in the different subgroups. Contrary to expectations, we did observe a tendency of longer PFS in CRS1/2 versus CRS3 for BRCAmut and HRD tumors, indicating no added value for CRS in these situations. In contrast, a tendency of better PARPi response in the CRS3 versus CRS1/2 was noticed in HRP subgroup, suggesting that platinum sensitivity according to CRS could predict a better PARPi response in HRP population.
    Clinical • PARP Biomarker • BRCA Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency) • BRCA (Breast cancer early onset)
    |
    BRCA MASTR Plus Dx • Myriad myChoice® CDx Plus • OncoKitDx
    |
    Lynparza (olaparib) • Zejula (niraparib)
    10ms
    IMPACT OF MOLECULAR STATUS ON CHEMOTHERAPY RESPONSE SCORE (CRS) IN ADVANCED EPITHELIAL OVARIAN CANCER (AEOC) (ESGO 2024)
    Conclusion In our cohort, BRCA1/2-mutated pts and HRD showed a trend towards a better response to NACT as opposed to BRCA-WT and HR proficient pts, according to CRS, although statistical significance is not reached due to the limited number of patients. Further research is guaranteed.
    BRCA Biomarker • Metastases
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • BRCA (Breast cancer early onset) • BRIP1 (BRCA1 Interacting Protein C-terminal Helicase 1)
    |
    BRCA2 mutation • BRCA1 mutation • ATM mutation • BRCA wild-type • BRIP1 mutation • BRCA mutation
    |
    BRCA MASTR Plus Dx • Myriad myChoice® CDx Plus • OncoKitDx